Literature DB >> 14531982

Imported Dengue in French University Hospitals: a 6-year survey.

Sékéné Badiaga1, Karine Barrau, Philippe Brouqui, Jacques Durant, Denis Malvy, François Janbon, Eric Bonnet, Annick Bosseray, Albert Sotto, Dominique Peyramont, Serge Dydymski, Celine Cazorla, Hervé Tolou, Jean Paul Durant, Jean Delmont.   

Abstract

Dengue fever (DF) is a mosquito-transmitted acute disease caused by any of four dengue flavivirus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4) which is becoming a major public health problem in intertropical areas.1 DF is increasingly observed in febrile travelers returning from tropical areas,2 especially those returning from the Caribbean islands and Southeast Asia, but it is rarely diagnosed in travelers returning from Africa.3-8 Diagnosis is often serologic, and in most cases is not confirmed; virus isolation remains exceptional. In a retrospective study of 44 cases of imported DF diagnosed in France, we found that the epidemiologic, clinical and diagnostic characteristics of these cases were similar to those reported in other previous published studies; diagnosis was carried out with serology, and no virus isolation was reported. To draw the attention of physicians from nonendemic areas to the possible occurrence of dengue infection in febrile travelers from all tropical countries, including those in Africa, and to reinforce recommendations required to establish diagnosis with certainty, we report herein a prospective study from 1998-1999 which we compiled with our previously published data.

Entities:  

Mesh:

Year:  2003        PMID: 14531982

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  5 in total

1.  Massilia timonae infection presenting as generalized lymphadenopathy in a man returning to Belgium from Nigeria.

Authors:  Amaryllis H Van Craenenbroeck; Kim Camps; Pierre Zachée; Ka Lung Wu
Journal:  J Clin Microbiol       Date:  2011-04-27       Impact factor: 5.948

2.  A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro.

Authors:  Suzanne J F Kaptein; Tine De Burghgraeve; Mathy Froeyen; Boris Pastorino; Marijke M F Alen; Juan A Mondotte; Piet Herdewijn; Michael Jacobs; Xavier de Lamballerie; Dominique Schols; Andrea V Gamarnik; Ferenc Sztaricskai; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

3.  Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006.

Authors:  Eli Schwartz; Leisa H Weld; Annelies Wilder-Smith; Frank von Sonnenburg; Jay S Keystone; Kevin C Kain; Joseph Torresi; David O Freedman
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

4.  Fever in travelers returning from tropical areas: prospective observational study of 613 cases hospitalised in Marseilles, France, 1999-2003.

Authors:  Philippe Parola; Georges Soula; Pierre Gazin; Cedric Foucault; Jean Delmont; Philippe Brouqui
Journal:  Travel Med Infect Dis       Date:  2006-03       Impact factor: 6.211

Review 5.  Uncovering the Burden of Dengue in Africa: Considerations on Magnitude, Misdiagnosis, and Ancestry.

Authors:  Emily Mary Gainor; Eva Harris; A Desiree LaBeaud
Journal:  Viruses       Date:  2022-01-25       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.